KLK3 and prostate cancer: A prior meta-analysis of the available medical literature up to December 2020 showed that the agent is associated with a relatively high detection rate among patients with BCR and that the rate of prostate cancer detection is highly dependent on the patient’s serum prostate-specific antigen (PSA) level [10].